Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Phase 1

Completed

• Conditions: Leukemia Lymphocytic Chronic B-Cell
• Interventions: Drug: CC-292; Drug: Lenalidomide

• Registration Number: NCT01732861
• Lead Sponsor: Celgene

Brief Summary

This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD). These data will be used to establish a Recommended Phase 2 Dose (RP2D) for the combination of CC-292 and lenalidomide in subjects with Chronic Lymphocytic Leukemia (CLL).

Detailed Description

This dose finding study uses a 3 + 3 dose escalation and expansion design to establish the recommended Phase 2 dose. The starting dose is CC-292 375 mg twice daily and Lenalidomide 10 mg once daily. After review of the data for dose limiting toxicities (DLTs), the second dose level will be enrolled. Doses for this second cohort are CC-292 500 mg twice daily and lenalidomide 10 mg once daily. Additional doses of lenalidomide in combination with CC-292 may be evaluated to accurately determine the maximum tolerated dose. Once the maximum tolerated dose and/or optimal biologic effect has been ascertained, an expansion cohort of 24 subjects may be enrolled.

Study Timeline

• Study First Submitted: 2012-11-14
• Study First Submitted QC: 2012-11-19
• Study First Posted: 2012-11-26
• Study Start: 2012-12-28
• Primary Completion: 2019-01-23
• Study Completion: 2019-01-23
• Status Verified: 2019-12
• Last Update Submitted: 2019-12-19
• Last Update Posted: 2019-12-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Male and female subjects 18 years of age and older at the time of signing the informed consent document (ICD).
• Body weight at least 50 kg.
• Must have a documented diagnosis of CLL/SLL (International Workshop on Chronic Lymphocytic Leukemia IWCLL Guidelines - Hallek 2008) by investigator assessment.
• Have failed at least 1 previous treatments for CLL/SLL, and have relapsed and/or refractory disease following last prior treatment defined as CLL/SLL that does not achieve at least a partial response (PR) to therapy or that progresses within 6 months of treatment.
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 or less.
• Life expectancy of at least 3 months from time of signing ICD.
• Females of childbearing potential (FCBP) must have a negative medically supervised pregnancy test prior to starting study therapy and agree to ongoing pregnancy testing during and after end of study therapy; commit to continued abstinence from heterosexual intercourse or agree to use, comply with two effective methods of contraception without interruption, 28 days prior to starting study drug, during study therapy, and for 28 days after discontinuation of study therapy.
• Male subjects must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy, throughout study drug therapy and dose interruption, and for 28 days after end of study therapy; agree to not donate semen or sperm during study drug therapy and for 28 days after end of study drug therapy.
• All subjects must understand that lenalidomide could have a potential teratogenic risk, agree to abstain from donating blood with taking lenalidomide therapy and following discontinuation of study drug therapy; have an echocardiogram (ECG) or multigated acquisition (MUGA) scan of the heart demonstrating left ventricular ejection fraction (LVEF) at least 50% or the institution's lower limit of normal; have recovered from adverse, toxic effects of prior therapies to equal to or less than 1 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.03 except for alopecia and peripheral neuropathy.

Exclusion Criteria

• Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

• Autologous stem cell transplant within 3 months prior to the time of signature on the ICD Informed Consent Document.

• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring parenteral antibiotics; uncontrolled diabetes mellitus; chronic symptomatic congestive heart failure; unstable angina pectoris, angioplasty, stenting, or myocardial infarctions within 6 months prior to the time of signature on the ICD; clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia. Subjects with controlled atrial fibrillation that is asymptomatic are eligible.

• Pregnant or lactating females.

• Prior history of malignancies, unless the subject has been free of the disease for 5 years or more prior to the time of signature on the ICD. Exceptions to the 5 years or more time limit include history of basal cell carcinoma of the skin; squamous cell carcinoma of the skin; carcinoma in situ of the cervix; carcinoma in situ of the breast; carcinoma in situ of the bladder; incidental histologic finding of prostate cancer (Tumor/Nodes/Metastasis [TNM] stage of T1a or T1b).

• Known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV).

• Known seropositivity for hepatitis C virus (HCV); hepatitis B virus (HBV).

• Subjects who are at a high risk for a thromboembolic event and are not willing/able to take venous thromboembolic event (VTE) prophylaxis.

• Any of the following laboratory abnormalities:

  1. Absolute Neutrophil Count (ANC) ≤ 1,000 cells/mm3 (1.0 x 109/L)
  2. Platelet count ≤ 50,000/mm3 (50 x 109/L) unless secondary to bone marrow involvement by recent bone marrow aspiration and bone marrow biopsy
  3. Serum Aspartate Transaminase/Serum Glutamic-Oxaloacetic Transaminase (AST/SGOT) or Alanine Transaminase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) > 3.0 x upper limit of normal (ULN) or > 5.0 x ULN in cases of documented liver involvement
  4. Serum bilirubin > 1.5 x ULN or > 3.0 x ULN in cases of Gilbert's Syndrome and documented liver involvement by lymphoma;
  5. Calculated creatinine clearance using the Cockcroft-Gault formula (Cockcroft,1976)
  6. Corrected QT interval (QTc) prolongation (defined as a QTc > 450 msec for males and > 470 msec for females [Fridericia's correction]) or other clinically significant ECG abnormalities as assessed by the investigator.

• Chemotherapy, radiotherapy, investigational anticancer therapy or major surgery within 28 days of Day 1 dosing.

• Use of systemic corticosteroids in doses greater than prednisone equivalent to 20 mg/day within 3 weeks prior to study drug dosing.

• Concomitant use of medicines known to cause QT prolongation or torsades de pointes.

• Chronic use of H2 antagonists or proton pump inhibitors or their use within 7 days of first dose.

• Gastrointestinal abnormalities including the inability to take oral medication, requiring intravenous alimentation, or prior surgical procedure affecting absorption.

• Prior treatment with Btk (Bruton's tyrosine kinase) inhibitors.

• Any live vaccinations within 3 weeks from first dose.

• History of hypersensitivity to immunomodulatory drugs (IMiDs) (eg, lenalidomide, thalidomide, pomalidomide).

• Disease transformation (ie, Richter's Syndrome [lymphomas] or prolymphocytic leukemia).

• Patients with uncontrolled hyper or hypothyroidism.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CC-292 + Lenalidomide	CC-292	-
CC-292 + Lenalidomide	Lenalidomide	-

Primary Outcome Measures

Name	Time	Method
Adverse Events	Up to 5 years	Number of participants with adverse events

Secondary Outcome Measures

Name	Time	Method
PK-t1/2	Up to 15 days	Estimate of the terminal elimination half-life in plasma
Percentage of Participants Who Have Received Some Form of Response	Up to 2 years	Response rate is defined as the percentage of participants who have achieved some form of response including: a Complete Response (CR), a CR with incomplete bone marrow recovery, a Nodular Partial Response (PR), a Nodal PR or a PR with lymphoctyosis) based on the International Workshop for Chronic Lymphocytic Leukemia and lymphoma guidelines (IWCLL).
PK-Cmax	Up to 15 days	Maximum observed plasma concentration
PK-Tmax	Up to 15 days	Time to maximum observed plasma concentration
PK-λz	Up to 15 days	Terminal phase rate constant, determined by linear regression of the terminal points of the log-linear plasma concentration-time curve. Visual assessment will be used to identify the terminal linear phase of the concentration
PK-AUC (0-t)	Up to 15 days	Area under the plasma concentration-time curve from time zero to time t, where t is the last measurable time point
PK-AUC0-∞	Up to 15 days	Area under the plasma concentration time curve from time zero extrapolated to infinity.

Trial Locations

Locations (11)

Universitatsklinik der PMU; 🇦🇹 Salzburg, Austria

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Medizinische Abteilung-Zentrum fur Onkologie und Hamatologie; 🇦🇹 Wien, Austria

Universitatsklinik fur Innere Medizin; 🇦🇹 Innsbruck, Austria

The West Clinic; 🇺🇸 Memphis, Tennessee, United States

Allgemeines Krankenhaus Wien; 🇦🇹 Wien, Austria

Hackensack University Medical Center; 🇺🇸 Hackensack, New Jersey, United States

AKh Linz; 🇦🇹 Linz, Austria

Horizon Oncology Center; 🇺🇸 Lafayette, Indiana, United States

Clearview Cancer Institute Oncology Specialties, P.C; 🇺🇸 Huntsville, Alabama, United States

Mount Sinai School of Medicine; 🇺🇸 New York, New York, United States